Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.
|Videos|September 25, 2012
Photos From the American Thyroid Association Annual Meeting
Author(s)Onclive Team
Photos from the 82nd Annual Meeting of the American Thyroid Association held in Quebec City, Canada, on September 19-23, 2012.
Advertisement
A collections of photos from both the 82nd Annual Meeting of the American Thyroid Association and Quebec City, Canada, the city that hosted the latest installment of the annual meeting from September 19-23, 2012.
The 2012 ATA meeting focused on the latest promising clinical and translational research into thyroid diseases and disorders. The speakers addressed recent advances in thyroidology, molecular markers and panels, targeted therapies, and optimal surgical stategies.
<<<
Advertisement
Related to this article
Sanja Dacic, MD, PhD, outlines advances that are reshaping molecular profiling in advanced non–small cell lung cancer and how to navigate these changes.
Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.
Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.
Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.
New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
3
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5